← Back to headlines
Royalty Pharma and Johnson & Johnson Announce $500M Autoimmune Drug Deal
Royalty Pharma and Johnson & Johnson have finalized a $500 million deal concerning an autoimmune drug, marking a significant collaboration in the pharmaceutical sector.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
